Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending February 2015. The report details the announcement of final overall survival (OS) results from the phase III COMBI-d clinical study regarding the combination therapy of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with BRAF V600E/K mutation-positive metastatic melanoma.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory announcement focused exclusively on clinical trial results and safety data.
Material Changes and Clinical Results
The primary material update is the final statistical analysis of the COMBI-d study, which demonstrated a statistically significant reduction in the risk of death for the combination therapy compared to dabrafenib monotherapy:
- Hazard Ratio (HR): 0.71 (95% CI: 0.55, 0.92, p=0.011).
- Study Population: 423 patients randomized across Australia, Europe, and the Americas.
- Progression-Free Survival (PFS): Previous data showed a 25% reduction in risk of progression/death (HR 0.75). Median PFS was 9.3 months for the combination versus 8.8 months for monotherapy.
- Regulatory Status: Completion of this study fulfills a post-marketing requirement for the FDA's Accelerated Approval of the combination in the USA. Final data is scheduled for submission to regulatory authorities in the coming months.
Outlook, Risks, and Safety Profile
Management commentary reinforces the scientific rationale for combining MEK and BRAF inhibitors. The safety profile was consistent with prior observations, though specific adverse events were noted:
- Common Adverse Events (≥20%): Pyrexia, fatigue, headache, nausea, chills, joint pain, diarrhea, rash, hypertension, and vomiting.
- Increased Incidence with Combination: Pyrexia (51% vs 28% for monotherapy), hyperkeratosis (32% vs 3% for monotherapy), and febrile reactions (71% vs 26%).
- Key Safety Warnings:
- New Primary Malignancies: Increased incidence of basal cell carcinoma (9% vs 2%) and cutaneous squamous cell carcinoma (7% vs 19% for monotherapy).
- Haemorrhage: Increased incidence (16% vs 2%) and severity; intracranial haemorrhage was fatal in 4% of combination patients.
- Venous Thromboembolic Events: DVT and PE occurred in 7% of combination patients versus 0% for monotherapy.
- Cardiomyopathy: Occurred in 9% of combination patients versus 0% for monotherapy.
- Ocular Toxicities: Includes retinal vein occlusion and pigment epithelial detachment.
Forward-Looking Statements: GSK cautions that projections are subject to risks and uncertainties, including those described in the 2013 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the timeline for regulatory submission of the final COMBI-d data to the FDA and other authorities.
- Confirm the commercial impact of the combination therapy approval on GSK's oncology portfolio revenue.
- Review the full safety data regarding new primary malignancies and haemorrhagic events in the context of long-term patient management.
- Check for any updates on the co-promotion rights with Japan Tobacco Inc. (JTI) regarding trametinib in Japan.